Takahisa Imamura Selected Research

Gingipain Cysteine Endopeptidases

7/2019	A natural anti-periodontitis agent, epimedokoreanin B, inhibits virulence activities of gingipains from Porphyromonas gingivalis.
1/2015	Cleavage of host cytokeratin-6 by lysine-specific gingipain induces gingival inflammation in periodontitis patients.
5/2014	Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-α and interleukin-1β but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain.
9/2009	Degradation of vascular endothelial thrombomodulin by arginine- and lysine-specific cysteine proteases from Porphyromonas gingivalis.
4/2008	Dual regulation of interleukin-8 production in human oral epithelial cells upon stimulation with gingipains from Porphyromonas gingivalis.
11/2005	Arginine-specific gingipains from Porphyromonas gingivalis stimulate production of hepatocyte growth factor (scatter factor) through protease-activated receptors in human gingival fibroblasts in culture.
11/2004	Activation of the kallikrein-kinin system and release of new kinins through alternative cleavage of kininogens by microbial and human cell proteinases.
12/2003	The biphasic virulence activities of gingipains: activation and inactivation of host proteins.
1/2003	The role of gingipains in the pathogenesis of periodontal disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takahisa Imamura Research Topics

Disease

11	Inflammation (Inflammations) 01/2021 - 10/2002
10	Neoplasms (Cancer) 01/2021 - 12/2003
8	Periodontitis 07/2019 - 01/2003
5	Infections 01/2022 - 01/2003
5	Disseminated Intravascular Coagulation 01/2017 - 03/2004
5	Sepsis (Septicemia) 01/2017 - 12/2007
5	Periodontal Diseases (Periodontal Disease) 01/2015 - 01/2003
5	Hemorrhage 11/2012 - 01/2003
4	Glomerulonephritis 01/2015 - 03/2004
4	Chronic Periodontitis 06/2006 - 01/2003
3	Hypotension (Low Blood Pressure) 04/2009 - 11/2004
3	Hypersensitivity (Allergy) 11/2004 - 10/2002
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 11/2012
2	Proteinuria 01/2021 - 01/2015
2	Arthus Reaction 01/2019 - 10/2002
2	Blood Coagulation Disorders 01/2017 - 10/2012
2	Bacterial Infections (Bacterial Infection) 11/2005 - 01/2003
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2019
1	Breast Neoplasms (Breast Cancer) 12/2018
1	Colonic Neoplasms (Colon Cancer) 12/2018
1	Colitis 12/2017
1	Suppuration 01/2017
1	Diarrhea 01/2017
1	Gastroenteritis 01/2017
1	Stomach Neoplasms (Stomach Cancer) 11/2016
1	Carcinoma (Carcinomatosis) 11/2016
1	Neoplasm Metastasis (Metastasis) 10/2016
1	Tongue Neoplasms (Tongue Neoplasm) 10/2016
1	Renal Cell Carcinoma (Grawitz Tumor) 04/2015
1	Interstitial Nephritis (Tubulointerstitial Nephritis) 01/2015
1	Nephrosclerosis 01/2015
1	Hematuria 01/2015

Drug/Important Bio-Agent (IBA)

10	Thrombin FDA Link 01/2021 - 10/2002
9	Gingipain Cysteine EndopeptidasesIBA 07/2019 - 01/2003
8	Cysteine Proteases (Cysteine Protease)IBA 07/2019 - 01/2003
7	FibrinIBA 01/2015 - 10/2002
6	Fibrinogen (Factor I)FDA Link 01/2017 - 01/2003
5	Anaphylatoxin C5a ReceptorIBA 01/2021 - 04/2013
5	Serine Proteases (Serine Protease)IBA 01/2017 - 12/2007
4	Thromboplastin (Tissue Factor)IBA 01/2021 - 10/2002
4	Peptides (Polypeptides)IBA 10/2016 - 11/2004
4	Peptide Hydrolases (Proteases)FDA Link 10/2014 - 01/2003
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2008 - 02/2003
3	Complement System Proteins (Complement)IBA 01/2019 - 10/2014
3	Pharmaceutical PreparationsIBA 12/2018 - 04/2006
3	AnaphylatoxinsIBA 11/2016 - 04/2013
3	CytokinesIBA 05/2014 - 04/2004
3	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 11/2012 - 01/2006
3	Blood Proteins (Serum Proteins)IBA 10/2012 - 07/2008
3	Virulence Factors (Pathogenicity Factors)IBA 09/2008 - 11/2005
3	TrypsinIBA 06/2006 - 01/2003
3	EnzymesIBA 11/2004 - 01/2003
2	Blood Coagulation Factors (Coagulation Factor)IBA 01/2021 - 04/2004
2	PolymersIBA 01/2021 - 12/2018
2	Matrix Metalloproteinases (MMPs)IBA 10/2016 - 04/2013
2	Biological ProductsIBA 04/2015 - 11/2004
2	antithrombin III-protease complexIBA 01/2015 - 11/2012
2	Amino Acids FDA Link 01/2015 - 01/2003
2	Fibrinolysin FDA Link 11/2012 - 01/2006
2	Arginine (L-Arginine)FDA Link 04/2006 - 05/2005
2	Proteins (Proteins, Gene)FDA Link 11/2005 - 01/2003
2	KininsIBA 11/2004 - 01/2003
1	Plasminogen Activator Inhibitor 1IBA 01/2022
1	boric acid (boron oxide hydroxide)IBA 01/2021
1	Glucosamine (Dona)IBA 01/2021
1	AlbuminsIBA 01/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	epimedokoreanin BIBA 07/2019
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2019
1	Dextran SulfateIBA 12/2018
1	pirarubicinIBA 12/2018
1	Therapeutic UsesIBA 12/2018
1	AzoxymethaneIBA 12/2018
1	anthraceneIBA 12/2018
1	Immunoglobulin A (IgA)IBA 12/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2017
1	MHC class II transactivator proteinIBA 12/2017
1	HLA-DR4 Antigen (HLA DR4 Antigen)IBA 12/2017
1	Prothrombin (Factor II)IBA 01/2017
1	Complement C5 (Complement 5)IBA 01/2017
1	Superoxides (Superoxide)IBA 01/2017
1	Type I Tumor Necrosis Factor ReceptorsIBA 10/2016
1	AngiopoietinsIBA 10/2016
1	Messenger RNA (mRNA)IBA 10/2016
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 04/2015
1	Lysine (L-Lysine)FDA Link 01/2015
1	GlucocorticoidsIBA 01/2015
1	Keratin-6 (Keratin 6A)IBA 01/2015
1	C-Reactive ProteinIBA 01/2015
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2015
1	AntigensIBA 01/2015
1	Culture MediaIBA 10/2014

Therapy/Procedure

4	Therapeutics 01/2019 - 01/2003
2	Castration 01/2021 - 11/2012
2	Intravenous Injections 01/2019 - 05/2005
1	Cystectomy 11/2016
1	Nephroureterectomy 11/2016
1	Lasers (Laser) 01/2015